Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05235464 · ClinicalTrials.gov registry record · NA

High Protein Diet and Atherosclerosis

A NA study of Atherosclerosis, sponsored by University of Missouri-Columbia.

Recruiting
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT05235464: Recruiting NA study of Atherosclerosis, sponsored by University of Missouri-Columbia.

NCT05235464 is a NA study of Atherosclerosis that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 24 participants, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05235464, a NA study of Atherosclerosis, is actively recruiting participants, sponsored by University of Missouri-Columbia.

RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

Atherosclerosis is the underlying cause of the majority of cardiovascular diseases, including myocardial infarction and strokes, and results in tremendous morbidity and mortality. A Western-type diet is a major risk factor for atherosclerosis because of the high saturated fat, cholesterol, and refined carbohydrate contents. Dietary strategies to reduce cardiovascular disease burden therefore focus on restriction of saturated fat, cholesterol, and refined carbohydrates whereas "lean" protein intake is recommended and has become popular. However, results from studies conducted in animal models suggest high dietary protein intake is also atherogenic. The investigators' extensive preliminary data in animal models show that dietary protein increases atherosclerotic plaque formation and size and promotes necrotic core formation, a characteristic of rupture-prone plaques. The goal of the current proposal is to provide deeper insights into the relationship between protein intake and the pathogenesis of atherosclerosis by studying the mechanisms involved in protein-mediated atherogenesis and formation of necrotic plaques. The overarching hypothesis is that high protein intake drives atherosclerosis via leucine-mediated mTORC1 signaling in macrophages, which inhibits macrophage mitophagy and aggrephagy and stimulates macrophage proliferation. Furthermore, the investigators hypothesize that proteins from animal sources are more atherogenic than proteins from plant sources, because animal proteins contain more leucine than plant proteins. The investigators will test these hypotheses by using a sophisticated array of experimental strategies, including assays in primary macrophages and human monocyte-derived macrophages and genetically engineered mouse models. In addition, they will begin to translate the results obtained in vitro and in animals to people, and explore approaches to pharmacologically target the pro-atherogenic pathways as novel cardiovascular therapeutics. This pr

Primary Outcome

Change in proatherogenic pathway activation

Conditions Studied

Interventions

  • OTHER Standard meal
  • OTHER High animal protein meal
  • OTHER High plant protein meal
  • OTHER High plant protein meal with additional leucine

Study Locations (1)

Missouri

  • University of Missouri School of Medicine - Columbia

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2023-03-13
Est. Completion 2028-03-31
Phase NA
University of Missouri-Columbia

291 total trials

What NCT05235464 shows while recruiting

NCT05235464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 4 interventions - of which Standard meal is the first listed.

NCT05235464 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT05235464 about?

NCT05235464 is a clinical study titled "High Protein Diet and Atherosclerosis". Atherosclerosis is the underlying cause of the majority of cardiovascular diseases, including myocardial infarction and strokes, and results in tremendous morbidity and mortality. A Western-type diet is a major risk factor for atherosclerosis because of the high saturated fat, cholesterol, and refin...

What is the current status of trial NCT05235464?

This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2023-03-13. Estimated completion is 2028-03-31.

What conditions does trial NCT05235464 study?

This clinical trial studies the following conditions: Atherosclerosis.

What interventions are being tested in trial NCT05235464?

The interventions under investigation include: Standard meal (OTHER), High animal protein meal (OTHER), High plant protein meal (OTHER), High plant protein meal with additional leucine (OTHER).

Who is sponsoring clinical trial NCT05235464?

This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05235464 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atherosclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05235464's enrollment target sits among peer trials

24 67th of 69 higher than 2 of 69 other Atherosclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05235464, the US trial registry maintained by the National Library of Medicine. NCT05235464 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.